

Organizing Committee

Chairman

Gert Kostner, Graz, AT



Vice-Chairmen



Hans Dieplinger
Innsbruck, AT



Florian Kronenberg
Innsbruck, AT

Local Members

Winfried März, Graz, AT
Gerd Utermann, Innsbruck, AT

International Advisory Board

Alberico Catapano, Milano, IT
M. John Chapman, Paris, FR
Henry N. Ginsberg, New York, USA
Pia Kamstrup, Copenhagen, DK
Marlys Koschinsky, Windsor, CA
Karam Kostner, Brisbane, AUS
Santica Marcovina, Seattle, USA
Sally McCormick, Dunedin, NZ
Børge Nordestgaard, Copenhagen, DK
Sotirios Tsimikas, San Diego, USA
Olaf Wiklund, Gothenburg, SE

Lp(a) Satellite Symposium

Lp(a) Satellite Meeting

From Bench to Bedside
Innsbruck, May 27-28, 2016

Venue

University of Innsbruck, Austria

Conference Hotel

Hotel Grauer Bär
Universitätsstraße 5-7, 6020 Innsbruck, Austria
<http://www.innsbruck-hotels.at/hotel-grauer-baer>

PCO

pdl - Dr. Eugen Preuß
Andreas-Hofer-Straße 6 EG, 6020 Innsbruck, Austria
T +43 512 567303
<http://www.congressinfo.net>

Accreditation

This meeting will be submitted for accreditation by the Austrian Medical Association.

Exhibition

A supporting technical-scientific exhibition will be organized.

Conference webpage

Please visit <http://lpa.i-med.ac.at> for further information

Lp(a) Satellite Meeting

From Bench to Bedside
Innsbruck, May 27-28, 2016

Visit <http://lpa.i-med.ac.at>



This meeting is a satellite to the 84th EAS Congress to be held in Innsbruck from May 29 – June 1, 2016



Dear Colleagues and Friends,

Fifty years after the first report by Kåre Berg of Oslo, Lp(a) is finally accepted by the scientific community as a causal risk factor for atherosclerosis and cardiovascular diseases. Considering the great interest in Lp(a), it is astonishing how many gaps there are in our knowledge of its biological function and biosynthetic and catabolic pathways. A major obstacle to functional investigation of Lp(a) is the lack of suitable animal models and cell lines. Other, even more burning, questions pertain to the accurate measurement of Lp(a) plasma concentrations and apo(a) isoforms in the clinical laboratory.

Presently, there is no drug on the market that specifically lowers elevated Lp(a) in patients at increased risk for CVD. We therefore look with great hope to the results of clinical trials with new cholesterol-lowering drugs or, even more so, with medications that are specifically directed against Lp(a).









With the current strong interest in Lp(a) research in mind we decided to organize this International Lp(a) Symposium as a satellite to the 84th EAS Congress in Innsbruck and are very grateful to the EAS and its president Alberico Catapano for supporting our initiative for this symposium. We will bring together the leading experts in Lp(a) research, who have promised to share with us their views and their most recent results in order to promote our knowledge of this important risk factor for atherosclerosis.

Innsbruck (<http://www.innsbruck.at/>) is a charming city in the heart of Europe with an abundance of cultural, sightseeing and sports opportunities, not only in winter but all year 'round.

We enthusiastically look forward to the International Lp(a) Meeting and invite you to share this important event with us.


Gert M. Kostner
Florian Kronenberg, Hans Dieplinger

The following topics will be covered

-  **Biochemistry of Lp(a)**
Setting the stage and overview
-  **Lp(a) Metabolism**
Biosynthesis; catabolism; role of receptor binding and PCSK9
-  **Pathophysiology**
Role in atherogenesis, CVD, MI; thrombotic versus atherosclerotic settings; significance of Lp(a)-transported LpPLA2
-  **Importance of Lp(a) in Various Clinical Conditions**
Familial hypercholesterolemia, kidney diseases, type 2 diabetes mellitus
-  **Therapy of Elevated Lp(a)**
What clinicians need to know about Lp(a) and when to treat; currently available drugs affecting Lp(a); novel developments including injectables
-  **Focus on the Gene**
Sequence microheterogeneity; biology of small apo(a) isoforms; racial differences in Lp(a) concentrations; apo(a) isoform size distribution and clinical implications; recent insights from genetic epidemiologic studies on CHD risk
-  **Late Breaking Lp(a) Research**
Selection from submitted abstracts
-  **Workshop on Methodology**
Standardization of Lp(a) assays

Confirmed International
Chairpersons and Speakers

Alberico Catapano, Milan, IT
M. John Chapman, Paris, FR
Henry N. Ginsberg, New York, USA
Pia Kamstrup, Copenhagen, DK
Karam Kostner, Brisbane, AUS
Sally McCormick, Dunedin, NZ
Marlys Koschinsky, Windsor, CA
Santica Marcovina, Seattle, USA
Børge Nordestgaard, Copenhagen, DK
Sotirios Tsimikas, San Diego, USA
Olaf Wiklund, Gothenburg, SE



Innsbruck
May 27-28, 2016

Lp(a) Satellite Symposium